Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Department of Endocrinology and Metabolism, Faculty of Medicine, Kagawa University, 1750-1, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Eur J Pharmacol. 2018 Nov 5;838:78-84. doi: 10.1016/j.ejphar.2018.09.015. Epub 2018 Sep 7.
ATP-binding cassette transporter A1 (ABCA1) protein is a pivotal regulator of cholesterol and phospholipid efflux from cells to high-density lipoprotein (HDL) particles. Pancreatic ABCA1 functions in beta cell cholesterol homeostasis and affects insulin secretion. We investigated the effect of pemafibrate (K-877), a novel selective PPARα modulator (SPPARMα), on pancreatic ABCA1 expression. In vivo experiment, mice were divided into four treatment groups, namely, normal food plus placebo, high fat diet (HFD) plus placebo, normal food plus K-877 (0.3 mg/kg/day), or HFD plus K-877 (0.3 mg/kg/day), and treated for eight weeks. The results in vitro experiment indicate that K-877 treatment increased levels of ABCA1 mRNA, as well as protein, subsequently reduced the cellular cholesterol content in INS-1 cells. PPARα specific antagonist GW6471 attenuate K-877 induced ABCA1 expression in INS-1 cells. ABCA1 promoter activity increased with K-877 treatment at concentration 1 μM and 10 μM. Glucose-stimulated insulin secretion was ameliorated by K-877 treatment in INS-1 cells and isolated mouse islets. Although the expression of ABCA1 was reduced in mice with HFD treatment, both ABCA1 protein and mRNA levels were increased in mice with K-877 treatment. K-877 treatment improved glucose intolerance induced by HFD in mice. These findings raise the possibility that K-877 may affect insulin secretion by controlling ABCA1 expression in pancreatic beta cells.
三磷酸腺苷结合盒转运体 A1(ABCA1)蛋白是细胞内胆固醇和磷脂向高密度脂蛋白(HDL)颗粒外排的关键调节因子。胰腺 ABCA1 在β细胞胆固醇稳态中发挥作用,并影响胰岛素分泌。我们研究了新型选择性过氧化物酶体增殖物激活受体α调节剂(SPPARMα) pemafibrate(K-877)对胰腺 ABCA1 表达的影响。在体内实验中,将小鼠分为四组:正常饮食加安慰剂、高脂肪饮食(HFD)加安慰剂、正常饮食加 K-877(0.3mg/kg/天)或 HFD 加 K-877(0.3mg/kg/天),并治疗八周。体外实验结果表明,K-877 治疗增加了 ABCA1 mRNA 以及蛋白水平,随后降低了 INS-1 细胞内的细胞胆固醇含量。PPARα 特异性拮抗剂 GW6471 减弱了 K-877 诱导的 INS-1 细胞 ABCA1 表达。K-877 处理可增加 ABCA1 启动子活性,浓度为 1µM 和 10µM。K-877 治疗可改善 INS-1 细胞和分离的小鼠胰岛的葡萄糖刺激的胰岛素分泌。尽管 HFD 处理小鼠的 ABCA1 表达减少,但 K-877 治疗可增加 ABCA1 蛋白和 mRNA 水平。K-877 治疗可改善 HFD 诱导的小鼠葡萄糖不耐受。这些发现提示 K-877 可能通过控制胰腺β细胞中 ABCA1 的表达来影响胰岛素分泌。